Adamis Pharmaceuticals (ADMP) Reaches $2.95 52-Week Low; MFS Municipal Income Trust (MFM) Has 2.71 Sentiment

February 15, 2018 - By John Mackenzie

The stock decreased 0.15% or $0.0101 during the last trading session, reaching $6.6699. About 24,480 shares traded. MFS Municipal Income Trust (MFM) has declined 1.11% since February 15, 2017 and is downtrending. It has underperformed by 17.81% the S&P500.

The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) hit a new 52-week low and has $2.71 target or 8.00% below today’s $2.95 share price. The 6 months bearish chart indicates high risk for the $98.49 million company. The 1-year low was reported on Feb, 15 by Barchart.com. If the $2.71 price target is reached, the company will be worth $7.88M less. The stock decreased 14.49% or $0.5 during the last trading session, reaching $2.95. About 695,118 shares traded or 0.71% up from the average. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 52.09% since February 15, 2017 and is downtrending. It has underperformed by 68.79% the S&P500.

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma has $16 highest and $5 lowest target. $9.75’s average target is 230.51% above currents $2.95 stock price. Adamis Pharma had 9 analyst reports since December 1, 2015 according to SRatingsIntel. The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) earned “Buy” rating by Raymond James on Tuesday, September 12. The rating was maintained by Maxim Group with “Buy” on Monday, August 21. The stock has “Buy” rating by Maxim Group on Monday, June 12. The firm has “Buy” rating given on Monday, December 4 by Raymond James. The firm earned “Buy” rating on Tuesday, December 1 by Maxim Group. The rating was maintained by Maxim Group with “Buy” on Thursday, July 21.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $98.49 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

Robinson Capital Management Llc holds 0.36% of its portfolio in MFS Municipal Income Trust for 110,452 shares. Cutter & Co Brokerage Inc. owns 83,396 shares or 0.24% of their US portfolio. Moreover, Smith Moore & Co. has 0.24% invested in the company for 117,130 shares. The New York-based Mackay Shields Llc has invested 0.09% in the stock. Partnervest Advisory Services Llc, a California-based fund reported 15,986 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts